US FDA approves Retevmo for lung, thyroid cancers with certain genetic mutations EP News Bureau May 9, 2020 It is the first therapy approved specifically for cancer patients with the RET gene alterations
Lilly’s targeted RET drug shrinks tumours in lung cancer trial EP News Bureau Sep 16, 2019 Lilly’s drug, now called selpercatinib, is intended for patients with rare RET abnormalities, which occur in about 2 per cent of…
